Blue Cross NC policies

Search Blue Cross NC's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

Checking prior authorization for 81599? Open Blue Cross NC’s official lists and confirm the member’s product there.

42 policies name 81599, those listing the fewest codes first. A policy that names a code may also list it as excluded.

Blue Cross NC policies
PolicyDetailsCodesSource
Gene Expression Profiling for Uveal Melanoma AHS- M2071AHS-M2071 · Commercial1Original policy ↗
Use of Common Genetic Variants to Predict Risk of Non-Familial Breast Cancer AHS-M2126AHS-M2126 · Commercial1Original policy ↗
Fibromyalgia Testing AHS - M2177M2177 · Commercial3Original policy ↗
Use of Common Genetic Variants to Predict Risk of Non-Familial Breast Cancer AHS - M2126M2126 · Commercial3Original policy ↗
Gene Expression Based Assays for Cancers of Unknown Primary AHS - M2065M2065 · Commercial4Original policy ↗
Molecular Profiling for Cancers of Unknown Primary Origin AHS- M2065AHS-M2065 · Commercial4Original policy ↗
Genetic Testing for Macular Degeneration AHS-M2083AHS-M2083 · Commercial5Original policy ↗
Genetic Testing and Genetic Expression Profiling in Patients with Uveal Melanoma AHS - M2071M2071 · Commercial6Original policy ↗
Molecular Markers in Fine Needle Aspirates of the Thyroid AHS - M2108M2108 · Commercial6Original policy ↗
Multigene Expression Assay for Predicting Colon Cancer Recurrence AHS-M2111AHS-M2111 · Commercial6Original policy ↗
Oral Screening Lesion Identification Systems and Genetic Screening AHS – G2113G2113 · Commercial6Original policy ↗
ANA/ENA Testing AHS – G2022G2022 · Commercial7Original policy ↗
Laboratory Procedures Reimbursement Policy AHS - R2162R2162 · Commercial7Original policy ↗
Molecular Panel Testing of Cancers to Identify Targeted Therapy AHS - M2109M2109 · Commercial8Original policy ↗
Biomarker Testing for Autoimmune Rheumatic Disease AHS – G2022G2022 · Commercial9Original policy ↗
Oral Cancer Screening and Testing AHS - G2113G2113 · Commercial11Original policy ↗
BRAF Genetic Testing In Patients With Melanoma AHS-M2029AHS-M2029 · Commercial12Original policy ↗
Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease AHS - G2110G2110 · Commercial12Original policy ↗
Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease AHS - G2110G2110 · Commercial12Original policy ↗
Genetic Testing for Ophthalmologic Conditions AHS-M2083AHS-M2083 · Commercial13Original policy ↗
Testing for Colorectal Cancer Management AHS - M2026M2026 · Commercial13Original policy ↗
Molecular Markers in Fine Needle Aspirates of the ThyroidM2108 · Commercial15Original policy ↗
Biomarker Testing for Autoimmune Rheumatic Disease AHS - G2022 NotificationG2022 · Commercial16Original policy ↗
Biomarker Testing for Autoimmune Rheumatic Disease AHS - G2022G2022 · Commercial17Original policy ↗
Proteogenomic Testing of Individuals with Cancer AHS - M2168M2168 · Commercial20Original policy ↗
Transplant Rejection Testing AHS - M2091M2091 · Commercial21Original policy ↗
Molecular Diagnostics for Breast Cancer Prognosis AHS - M2020M2020 · Commercial22Original policy ↗
Prenatal Screening for Fetal Aneuploidy AHS –G2055G2055 · Commercial24Original policy ↗
Transplant Rejection Testing AHS - M2091 NotificationM2091 · Commercial24Original policy ↗
Prenatal Testing for Fetal Aneuploidy AHS - G2055G2055 · Commercial30Original policy ↗
General Genetic Testing, Somatic Disorders AHS-M2146AHS-M2146 · Commercial54Original policy ↗
Prenatal Screening (Genetic) AHS – M2179M2179 · Commercial54Original policy ↗
Cardiovascular Disease Risk Assessment AHS – G2050G2050 · Commercial56Original policy ↗
Cardiovascular Disease Risk Assessment AHS – G2050G2050 · Commercial60Original policy ↗
Cardiovascular Disease Risk Assessment AHS – G2050 NotificationAHS-G2050 · Commercial60Original policy ↗
Prenatal Screening (Genetic) AHS - M2179M2179 · Commercial67Original policy ↗
Prenatal Screening (Genetic) AHS - M2179 NotificationM2179 · Commercial67Original policy ↗
Serum Tumor Markers for Malignancies AHS - G2124G2124 · Commercial78Original policy ↗
Laboratory Procedures Medical Policy AHS - R2162 NotificationAHS - R2162 · Commercial84Original policy ↗
General Genetic Testing, Somatic Disorders AHS - M2146AHS-M2146 · Commercial92Original policy ↗
Laboratory Procedures Medical Policy AHS - R2162AHS - R2162 · Commercial93Original policy ↗
Laboratory Procedures Medical Policy AHS - R2162 NotificationAHS - R2162 · Commercial95Original policy ↗

Back to Blue Cross NC · Blue Cross NC prior authorization CPT list

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.